The new findings here are (i) pulmonary tuft cell-like cancers across various histotypes have considerably overlapping gene expression profiles, including a hybrid tuft cell/ionocyte-like signature; (ii) tuft cell-like NECs and SQCC nevertheless exhibit distinct histotype-associated clinicopathological features; (iii) in vitro, tuft cell-like SCLCs show higher vulnerability to PARP/BCL2 co-inhibition than to either drug alone. The gene discussed is PARP1; the disease is cancer.